Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma
NCT00200577
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
70
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Interventions
DRUG:
TIL + IL2
Sponsor
Nantes University Hospital